{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Geiger RM"],"funding":["Intramural FDA HHS"],"pagination":["1679626"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12690487"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5"],"pubmed_abstract":["<h4>Background and purpose</h4>Nonclinical human cardiac new approach methodologies (NAMs), including human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) combined with multielectrode array (MEA) represent a highly predictive <i>in vitro</i> model for identifying drug-induced cardiac liabilities of individual drugs. Here, we extend the use of an <i>in vitro</i> cardiac NAM to evaluate the safety of a drug combination including moxifloxacin, an antibiotic, and QT prolonging drug, and cobicistat a pharmacokinetic booster shown to shorten repolarization <i>in vitro</i>.<h4>Methods</h4>To generate the <i>in vitro</i> cardiac NAM, MEA coupled with hiPSC-CMs were cultured for 7-8 days. Cells were treated with moxifloxacin and cobicistat individually or in combination and change"],"journal":["Frontiers in drug discovery"],"pubmed_title":["Towards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study."],"pmcid":["PMC12690487"],"funding_grant_id":["FD999999"],"pubmed_authors":["Geiger RM","Bhardwaj B","Blinova K","Serna C","Feaster TK"],"additional_accession":[]},"is_claimable":false,"name":"Towards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study.","description":"<h4>Background and purpose</h4>Nonclinical human cardiac new approach methodologies (NAMs), including human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) combined with multielectrode array (MEA) represent a highly predictive <i>in vitro</i> model for identifying drug-induced cardiac liabilities of individual drugs. Here, we extend the use of an <i>in vitro</i> cardiac NAM to evaluate the safety of a drug combination including moxifloxacin, an antibiotic, and QT prolonging drug, and cobicistat a pharmacokinetic booster shown to shorten repolarization <i>in vitro</i>.<h4>Methods</h4>To generate the <i>in vitro</i> cardiac NAM, MEA coupled with hiPSC-CMs were cultured for 7-8 days. Cells were treated with moxifloxacin and cobicistat individually or in combination and change","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-06T13:56:23.865Z","creation":"2026-05-31T03:09:58.944Z"},"accession":"S-EPMC12690487","cross_references":{"pubmed":["41383657"],"doi":["10.3389/fddsv.2025.1679626"]}}